232 related articles for article (PubMed ID: 32929472)
21. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019-2021.
Viñuela L; de Salazar A; Fuentes A; Serrano-Conde E; Falces-Romero I; Pinto A; Portilla I; Masiá M; Peraire J; Gómez-Sirvent JL; Sanchiz M; Iborra A; Baza B; Aguilera A; Olalla J; Espinosa N; Iribarren JA; Martínez-Velasco M; Imaz A; Montero M; Rivero M; Suarez-García I; Maciá MD; Galán JC; Perez-Elias MJ; García-Fraile LJ; Moreno C; Garcia F
J Med Virol; 2023 Dec; 95(12):e29287. PubMed ID: 38084763
[TBL] [Abstract][Full Text] [Related]
22. Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study.
Scherrer AU; Yang WL; Kouyos RD; Böni J; Yerly S; Klimkait T; Aubert V; Cavassini M; Battegay M; Hauser C; Calmy A; Schmid P; Bernasconi E; Günthard HF;
J Infect Dis; 2016 Aug; 214(3):399-402. PubMed ID: 27130429
[TBL] [Abstract][Full Text] [Related]
23. Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
McCluskey SM; Kamelian K; Musinguzi N; Kigozi S; Boum Y; Bwana MB; Muzoora C; Brumme ZL; Carrington M; Carlson J; Foley B; Hunt PW; Martin JN; Bangsberg DR; Harrigan PR; Siedner MJ; Haberer JE; Lee GQ
AIDS; 2021 Jun; 35(7):1083-1089. PubMed ID: 33635845
[TBL] [Abstract][Full Text] [Related]
24. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.
Sayan M; Gündüz A; Ersöz G; İnan A; Deveci A; Özgür G; Sargın F; Karagöz G; İnci A; İnan D; Ülçay A; Karaoğlan I; Kaya S; Kutlu SS; Süer K; Çağatay A; Akalın H
HIV Clin Trials; 2016 May; 17(3):109-13. PubMed ID: 27125365
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.
Wenk BM; Mbunkah HA; Nsanwe NN; Mbu ET; Besong LM; Sama BA; Orock E; Leemann C; Metzner KJ
J Antimicrob Chemother; 2021 Jan; 76(1):124-129. PubMed ID: 32954411
[TBL] [Abstract][Full Text] [Related]
26. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
[TBL] [Abstract][Full Text] [Related]
27. Preliminary report of transmitted drug resistance to integrase strand chain transfer inhibitors in treatment-naïve HIV infected patients.
Ferrer P; Ramos V; Puente MI; Afani A
Diagn Microbiol Infect Dis; 2023 Dec; 107(4):116083. PubMed ID: 37778156
[TBL] [Abstract][Full Text] [Related]
28. Virological response to integrase strand transfer inhibitor-based antiretroviral combinations in HIV-1 group O-infected patients.
Alessandri-Gradt E; Unal G; Leoz M; Plantier JC;
AIDS; 2019 Jul; 33(8):1327-1333. PubMed ID: 30950879
[TBL] [Abstract][Full Text] [Related]
29. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.
Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Rinke de Wit TF; Paredes R
J Antimicrob Chemother; 2018 May; 73(5):1167-1172. PubMed ID: 29462322
[TBL] [Abstract][Full Text] [Related]
30. Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy.
Gibson RM; Weber J; Winner D; Miller MD; Quiñones-Mateu ME
PLoS One; 2014; 9(8):e104512. PubMed ID: 25110880
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.
De Francesco MA; Izzo I; Properzi M; Gargiulo F; Caccuri F; Quiros-Roldan E; Castelli F; Caruso A; Focà E
AIDS Res Hum Retroviruses; 2018 Jul; 34(7):570-574. PubMed ID: 29631420
[TBL] [Abstract][Full Text] [Related]
32. Low level of HIV-1C integrase strand transfer inhibitor resistance mutations among recently diagnosed ART-naive Ethiopians.
Kiros M; Tefera DA; Andualem H; Geteneh A; Tesfaye A; Woldemichael TS; Kidane E; Alemayehu DH; Maier M; Mihret A; Abegaz WE; Mulu A
Sci Rep; 2023 Apr; 13(1):6546. PubMed ID: 37085698
[TBL] [Abstract][Full Text] [Related]
33. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
[TBL] [Abstract][Full Text] [Related]
34. Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.
Arimide DA; Szojka ZI; Zealiyas K; Gebreegziabxier A; Adugna F; Sasinovich S; Björkman P; Medstrand P
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458459
[TBL] [Abstract][Full Text] [Related]
35. Primary resistance to integrase inhibitors in Shenzhen.
Zhu Y; Huang Y; Zheng C; Tang J; Zeng G; Xie W; Wang H; Zhang L; Liu S; Zhang Y; Tan W; Tan J; Jiang L; He Y; Xu L; Yang Z; Zhao J
J Antimicrob Chemother; 2023 Feb; 78(2):546-549. PubMed ID: 36585770
[TBL] [Abstract][Full Text] [Related]
36. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
Mboumba Bouassa RS; Mossoro-Kpinde CD; Gody JC; Veyer D; Péré H; Matta M; Robin L; Grésenguet G; Charpentier C; Bélec L
J Antimicrob Chemother; 2019 Jul; 74(7):2030-2038. PubMed ID: 30891603
[TBL] [Abstract][Full Text] [Related]
37. Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey.
Kamori D; Barabona G; Rugemalila J; Maokola W; Masoud SS; Mizinduko M; Sabasaba A; Ruhago G; Sambu V; Mushi J; Mgomella GS; Mcollogi JJ; Msafiri F; Mugusi S; Boniface J; Mutagonda R; Mlunde L; Amani D; Mboya E; Mahiti M; Rwebembera A; Ueno T; Pembe A; Njau P; Mutayoba B; Sunguya B
J Antimicrob Chemother; 2023 Mar; 78(3):779-787. PubMed ID: 36680436
[TBL] [Abstract][Full Text] [Related]
38. Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings.
Semengue ENJ; Armenia D; Inzaule S; Santoro MM; Dambaya B; Takou D; Teto G; Nka AD; Yagai B; Fabeni L; Chenwi C; Angong Beloumou G; Djupsa Ndjeyep SC; Colizzi V; Perno CF; Ceccherini-Silberstein F; Fokam J
J Antimicrob Chemother; 2021 Apr; 76(5):1277-1285. PubMed ID: 33501504
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon.
Mikasi SG; Gichana JO; Van der Walt C; Brado D; Obasa AE; Njenda D; Messembe M; Lyonga E; Assoumou O; Cloete R; Ikomey GM; Jacobs GB
AIDS Res Hum Retroviruses; 2020 May; 36(5):450-455. PubMed ID: 31830799
[TBL] [Abstract][Full Text] [Related]
40. Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study.
Celotti A; Gargiulo F; Quiros-Roldan E; Properzi M; De Francesco MA; Coletto D; Caccuri F; Izzo I; Caruso A; Castelli F; Focà E
HIV Res Clin Pract; 2020 Feb; 21(1):24-33. PubMed ID: 32141388
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
